VANCOUVER, BRITISH COLUMBIA--(Marketwire - February 07, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that it has closed, via a non-brokered private placement, an offering of 5,250,000 units at a price of $0.20 per unit for gross proceeds to the Company of $1,050,000 (the "Offering"). The Company's management team and Board of Directors subscribed for an aggregate of 1,362,500 units in the Offering.
